3 enrolling by invitation. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Enrolling by invitation 3 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone - Plasma Cell Myeloma | Phase 2 | Enrolling by invitation | Sanofi | 70 | 2023-04-05 | 2026-10-15 |
| A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) Carfilzomib, Lenalidomide, Dexamethasone - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 2 | Enrolling by invitation | Landspitali University Hospital | 80 | 2019-06-24 | 2019-08-16 |
| Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells AUTO CAR T cell therapy - Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma | Phase 2 | Enrolling by invitation | Autolus Limited | 500 | 2018-08-02 | 2026-09-22 |
Multiple Myeloma (3) · Lymphoma, T-Cell (1) · Smoldering Multiple Myeloma (1)
Blood Protein Disorders (3) · Cardiovascular Diseases (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Hemorrhagic Disorders (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Plasma Cell (3) · Paraproteinemias (3) · Vascular Diseases (3) · Hypergammaglobulinemia (1)
Dexamethasone (2) · Lenalidomide (2) · carfilzomib (2) · cemiplimab (1) · isatuximab (1) · pomalidomide (1)
Autolus Limited (1) · Landspitali University Hospital (1) · Sanofi (1)
Spain (2) · United States (2) · Australia (1) · Brazil (1) · Chile (1) · China (1) · Czechia (1) · Finland (1) · France (1) · Greece (1) · Iceland (1) · Italy (1) · Japan (1) · New Zealand (1) · Russia (1)
Sigurdur Y Kristinsson, MD, PhD (1)
2023 (1)